Lymph node dissection in patients with differentiated thyroid carcinoma - who benefits?

1998 ◽  
Vol 383 (5) ◽  
pp. 355-358 ◽  
Author(s):  
B. Mann ◽  
H. J. Buhr
2020 ◽  
Vol 17 (4) ◽  
pp. 317-338
Author(s):  
Maria V Deligiorgi ◽  
Mihalis I Panayiotidis ◽  
Dimitrios T Trafalis

Considering the ‘differentiated thyroid carcinoma (DTC) epidemic’, the indolent nature of DTC imposes a treatment paradigm shift toward elimination of recurrence. Lymph node metastases in cervical compartments, encountered in 20–90% of DTC, are the main culprit of recurrent disease, affecting 5–30% of patients. Personalized risk-stratified cervical prophylactic lymph node dissection (PLND) at initial thyroidectomy in DTC with no clinical, sonographic or intraoperative evidence of lymph node metastases (clinically N0) has been advocated, though not unanimously. The present review dissects the controversy over PLND. Weighing the benefit yielded from PLND up against the PLND-related morbidity is so far hampered by the inconsistent profit yielded by PLND and the challenging patient selection. Advances in tailoring PLND are anticipated to empower optimal patient care.


2013 ◽  
Vol 37 (7) ◽  
pp. 1584-1591 ◽  
Author(s):  
Romain Ducoudray ◽  
Christophe Trésallet ◽  
Gaelle Godiris-Petit ◽  
Frédérique Tissier ◽  
Laurence Leenhardt ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document